Thursday, October 23, 2025

3:40 PM - 4:25 PM

Momentum Room

---

Details

Liquid biopsy is transforming oncology by enabling real-time, non-invasive tumor profiling for early diagnosis, treatment monitoring, and minimal residual disease (MRD) detection. Its integration into clinical trials enhances patient stratification, supports adaptive designs, and enables longitudinal tracking of tumor dynamics—critical for guiding treatment decisions months before relapse appears. Advances in sequencing sensitivity now detect mutations at 0.01% allele frequency, expanding applications from metastatic disease to early detection and surveillance. Diagnostic labs and integrated platforms combining ctDNA analysis, NGS, and companion diagnostics accelerate enrollment and improve endpoint precision. Embedding liquid biopsy data into Customer Data Platforms ensures traceability, regulatory compliance, and secure consent-driven management across global markets, streamlining evidence generation and market access. This session will include a brief introduction followed by a panel discussion covering Australia’s perspective in the race to master the full precision oncology ecosystem—from assays and databases to algorithms and partnerships.

---

Speaker